Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3

Nefrologia. 2016;36(1):72-5. doi: 10.1016/j.nefro.2015.07.007. Epub 2015 Nov 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome / drug therapy*
  • Atypical Hemolytic Uremic Syndrome / genetics
  • Complement C3
  • Complement Factor I
  • Hemolytic-Uremic Syndrome / drug therapy
  • Humans
  • Mutation

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement C3
  • eculizumab
  • Complement Factor I